The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

(2018) Brian B. Hasinoff et al.   Cardiovascular Toxicology

TOP2B: The First Thirty Years

(2018) Caroline Austin et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A subcellular map of the human proteome

(2017) Peter J. Thul et al.   SCIENCE

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

(2016) Brian B. Hasinoff et al.   Cardiovascular Toxicology

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

(2015) Folefac Aminkeng et al.   NATURE GENETICS

Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo

(2015) Anna Jirkovská-Vávrová et al.   Toxicology Research

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

(2014) Shiwei Deng et al.   BMC CANCER

A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation

(2013) Adam B. Shapiro et al.   ANALYTICAL BIOCHEMISTRY

Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity

(2013) P Vejpongsa et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat

(2011) Eugene H. Herman et al.   TOXICOLOGIC PATHOLOGY

The use of dexrazoxane for the prevention of anthracycline extravasation injury

(2008) Brian B Hasinoff   EXPERT OPINION ON INVESTIGATIONAL DRUGS